| Date | Title | Description |
| 25.07.2025 | Dispatch Bio Launched With $216 Million To Develop Solid Tumor Treatments | Dispatch Bio has officially launched with a mission to create a universal treatment for solid tumors, which constitute roughly 90% of cancers. The company has secured a total of $216 million in funding, including a recent Series A round.
Th... |
| 09.10.2024 | City Therapeutics: $135 Million (Series A) Raised For RNAi-Based Medicine | City Therapeutics announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. And City Therapeutics aims to utilize next-generation engineering of small interfering RNAs (siRNAs) – which is the “trigger”... |
| 03.06.2024 | Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors | PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member ... |
| 31.05.2024 | BioStock: She is CombiGene’s new CSO | BioStock: She is CombiGene’s new CSO
Fri, May 31, 2024 10:43 CET Report this content
CombiGene’s former Director Preclinical Development Annika Ericsson has taken over the role of the company’s Chief Scientific Officer. BioStock contacted E... |
| 07.05.2024 | Brandywine Realty Trust says data stolen in ransomware attack | U.S. realty trust giant Brandywine Realty Trust has confirmed a cyberattack that resulted in the theft of data from its network.
In a filing with regulators on Tuesday, the Philadelphia-based Brandywine described the cybersecurity incident ... |
| 07.05.2024 | Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C. | Prevent Blindness to host the 2024 ASPECT Patient Engagement and Advocacy Summit and Eyes on Capitol Hill event in Washington, D.C., May 14-16, 2024.
Three-day event brings together patients, care partners, and public health champions to ad... |
| 24.04.2024 | Prevent Blindness Declares May as First-ever Inherited Retinal Disease (IRD) Genetic Testing Awareness Month | Prevent Blindness declares the month of May as "Inherited Retinal Disease Genetic Testing Awareness Month."
Prevent Blindness expands IRD and genetic testing awareness initiative to educate patients on various forms of IRDs, and t... |
| 17.04.2024 | World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders" | MONTREAL, April 17, 2024 /PRNewswire/ -- On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day. The theme of the event this year is "Equitable access for all: recognizing all bl... |
| 09.05.2023 | Prevent Blindness Declares Fourth Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 15-21 | Prevent Blindness declares May 15-21, 2023, as the 4th annual “Inherited Retinal Disease (IRD) Genetic Testing Week." “By providing IRD patients with the resources they need to learn more about their diagnosis, as well as how gene ther... |
| 11.05.2022 | Prevent Blindness Declares Third Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22 | To help save sight, Prevent Blindness declares May 16-22 as the Third Annual Inherited Retinal Disease (IRD) Genetic Testing Week. as May 16-22 “Through early detection, specifically through genetic testing, and treatment, severe vision los... |
| 10.05.2022 | The POWER of Professional Women Honors Allies for Women in Business at the 2022 Advocate Awards | Executive leaders from Day & Zimmermann and Santander Bank, N.A. will be recognized for their advocacy of gender equality and a no-limits workplace. PHILADELPHIA, PENNSLYVANIA, UNITED STATES, May 10, 2022 /EINPresswire.com/ -- Interview... |
| 12.10.2021 | Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG01 | PHILADELPHIA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disea... |
| 14.05.2021 | Prevent Blindness Declares Second Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22 | Prevent Blindness declares May 16-22, 2021, as it's second annual “Inherited Retinal Disease (IRD) Genetic Testing Week” “By encouraging the public to educate themselves about IRDs and the positive impact that genetic testing may have on th... |
| 30.11.2020 | Navigating the challenge of covering breakthrough therapies at MedCity INVEST Precision Medicine | Our virtual MedCity INVEST Precision Medicine conference, December 9-11, will highlight aspects of precision medicine from the biopharma companies developing cell and gene therapies to diagnostics and the data sharing initiatives to support... |
| 24.11.2020 | Mark your calendars for our virtual INVEST Precision Medicine conference, December 9-11 | What Does the Diagnostics Landscape Look Like?
Diagnostics is joined at the hip with precision medicine. The rapidly evolving field has led to the ability to quickly, reliably and affordably sequence an individual’s entire genome and the de... |
| 16.05.2019 | Installment payments could be used across gene therapy space, Spark CEO says | “Certainly, we are continuously optimistic, but we would like to see the pace of policy changes we want to make happen more quickly,” Marrazzo told Veeva President Matt Wallach. “There are reasons why the government takes time to think thro... |
| 29.04.2019 | Report: Takeda adopts value-based pricing for Crohn’s stem cell therapy in Europe | Despite winning EMA approval for complex perianal fistulas in Crohn’s more than a year ago, Alofisel has encountered some difficulties securing so-called tertiary approval, a term used to refer to national-level payer coverage. UK drug-pric... |
| 25.02.2019 | Spark Therapeutics enters into definitive merger agreement with Roche | Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion. Spark Therapeutics will continue its operations in Philadelphia as an independent company within the Roche Group Transaction expect... |
| 25.02.2019 | Term Sheet — Monday, February 25 | TECH INTIMACY
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
I first learned about this company from Josh Wolfe, the co-founder and managing partner of Lux Capital, who invested in th... |
| 19.12.2018 | Developing a new gene therapy was hard. So was figuring out how to get it to patients | After a career spent in pharmaceutical commercial strategy and operations, I thought I had a handle on what was required to launch a new therapy. But I’ve learned many lessons — and faced a few curveballs — in the 12 months since the FDA ap... |
| 27.11.2018 | Spark, Novartis’s inherited blindness therapy Luxturna wins approval in Europe | Luxturna is a viral vector-based gene therapy that uses an adeno-associated viral vector to provide a working copy of the RPE65 gene to act in place of the mutated gene that leads to vision loss in patients with RPE65-associated inherited r... |
| 21.09.2018 | Novartis, Spark make positive step toward gene therapy Luxturna’s European approval | Under an agreement between the two companies, Novartis is marketing Luxturna in markets outside the US. Based in London, but planning to relocate to Amsterdam following the UK’s exit from the European Union, the EMA regulates drugs across t... |
| 08.05.2018 | Atara enlists Juno co-founder Michel Sadelain in CAR-T effort; Valeant no more, Bausch is the new marquee name | Michel Sadelain
→ The day after Atara announced that it is bringing Genentech vet Dietmar Berger on board as R&D chief, the biotech is back with a signed deal aimed at expanding its work with Memorial Sloan Kettering on o... |
| 03.05.2018 | How much would you pay for the miracle of gene therapy? | Every day I wake up thinking about how to get gene therapy to the children who will benefit from this breakthrough treatment. Right after that I start thinking about how we will pay for it.
I am not a doctor or a researcher or an employee o... |
| 03.01.2018 | Spark Therapeutics Announces Pricing and First-of-their-kind Patient Access Programs | |
| 20.12.2017 | Spark Therapeutics’ new FDA approval shows gene therapies are officially on fire | It’s a historic moment for many in the industry, including FDA Commissioner Scott Gottlieb who has overseen the approval of two others gene therapies, Kymriah and Yescarta, in the past five months.
“The culmination of decades of research ha... |
| 19.12.2017 | FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl) | Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that the U.S. Food and Drug Administration (FDA) has approved LUXTURNA™ (voretigene nep... |
| 30.10.2017 | Gene editing remains early stage, but Big Pharma has taken notice | In its recent report, titled Gene Editing: The Next Breakthrough in Regenerative Medicine, Informa Pharma Intelligence answers those questions with a focus on three major existing technologies: CRISPR/Cas9, zinc-finger nucleases (ZFNs), and... |
| 20.09.2017 | The Biotech Devil’s Dictionary: Your guide to the inanities of industry jargon | Biotech can be a breeding ground for jargon, coded language, and outright nonsense, as investors and scientists probe the depths of linguistic absurdity to explain why the thing they do is just that much more special than all the other thin... |
| 29.06.2017 | What’s Militia Hill Ventures’ take on biotech, cancer therapy investment? (Q&A) | What informs your investment strategy for Militia Ventures?
At Militia Hill Ventures, we build biotech companies from the ground up, bringing the team, the capital, and the assets together. We look at investments that have transformative po... |
| 10.05.2017 | Pfizer and Sangamo ink a $545M hemophilia-gene therapy deal | In return for global commercialization rights, Pfizer will pay $70 million upfront and up to $475 million in milestone payments that encourage both the commercialization of SB-525 and the development of new hemophilia A therapies.
With fres... |
| 05.12.2016 | Can Alnylam rise from the ASHes? | Now in San Diego, California, for the 58th American Society of Hematology (ASH) meeting, Alnylam desperately needs to change the conversation.
So what’s new? Pushkal Garg, Alnylam’s SVP of clinical development, met with MedCity News at ASH ... |
| 26.08.2016 | Sofinnova Ventures has raised $595M for its largest fund to date | The company’s strategy of investing in late-stage private companies has found some receptive buyers for those businesses, demonstrated by acquisitions of its portfolio companies from the likes of Teva, Shire and Pfizer.
And yet, it has also... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 15.06.2016 | Hemophilia ‘cures’ are proving gene therapy really is all it’s cracked up to be | Gene therapy is part of an increasingly large collection of research fields: those with a huge, useless backlog of innovations. Gene therapy researchers have spent decades developing amazing, world-changing therapies with absolutely no abil... |
| 08.03.2016 | Genable Technologies Investors Secure Spark Exit | Venture capital investors in TCD campus company Genable Technologies have secured an exit from the loss-making firm through the sale of the business to Nasdaq-quoted Spark Therapeutics.
As of February 2015, Genable had capital invested of €... |
| 19.05.2015 | Sidecar wins Tech Startup of the Year at PACT’s Enterprise Awards | Sidecar, the Center City digital marketing startup, won PACT’s Enterprise Award for Startup Technology Company of the Year last week.
Here’s a list of the other winners from the annual event:
Healthcare Innovator of the Year: Tabula Rasa He... |
| 28.11.2014 | Spark Therapeutics adds regulatory insider to support gene therapy for retinal degeneration | Romuald Corbau, former research project leader for Pfizer’s gene therapy program for the hepatitis C virus, joined as Spark’s translational research lead to help support the company’s pipeline of gene therapies.
Earlier this month Spark rec... |
| 10.07.2014 | Sofinnova appears to be bulking up a healthcare venture fund to $110 million | Sofinnova Ventures has a robust active portfolio. Some of its more notable funding rounds include participation in a $72.8 million Series B round with Spark Therapeutics, a $55 million C round with Coherus Bio Sciences and a $50 million rou... |
| 10.07.2014 | Venture-backed healthcare deals rise to $2.7B in Q2 | States accounting for the most deal activity Although Pennsylvania has a thriving biotechnology and healthcare community it doesn’t typically get as much recognition as California and Massachusetts. So it was interesting to see that Pennsyl... |
| 04.06.2014 | Sidecar raises $3.1M; Spark Therapeutics raises $72.8M [Startup Roundup] | WHO’S GETTING FUNDED?
Sidecar, the Center City ecommerce marketing company, raised $3.1 million in a round led by Bala Cynwyd-based Osage Venture Partners, CEO Andre Golsorkhi told us. All previous investors participated, including GSI Comm... |
| 28.05.2014 | Spark Therapeutics Raises $72.8M |
PHILADELPHIA, PA, Late-stage company developing gene-based medicines for a wide range of rare, debilitating diseases, today announced the successful completion of a $72.8M Series B financing.
>> Click here for more funding data on ... |
| 27.05.2014 | Spark Therapeutics’ late-stage gene therapy for inherited blindness takes a $73M step forward | Developed at CHOP’s Center for Cellular and Molecular Therapeutics, the therapy uses a neutralized virus as a vehicle to deliver a function gene to targeted cells in the eye. Once there, it enables production of a critical protein that’s mi... |
| 27.05.2014 | Spark Therapeutics Completes $72.8M Series B Financing | Spark Therapeutics, a Philadelphia, PA-based late-stage company developing gene-based medicines for a wide range of rare, debilitating diseases, completed a $72.8m Series B financing.
The round was led by Sofinnova Ventures, with participat... |
| 25.03.2014 | Gene therapy company Spark Therapeutics inks licensing deal for a retinitis pigmentosa gene therapy | Rhodopsin-linked autosomal dominant retinitis pigmentosa affects roughly 30,000 people worldwide and there are currently no drugs to treat it. Genable’s retinitis pigmentosa gene therapy is designed to suppresses the expression of faulty an... |
| 15.01.2014 | Sidecar raises $1M from local investors like Michael Rubin [Startup Roundup] | WHO’S GETTING FUNDED?
Rick Nucci‘s stealth mode startup, Guru Technologies, has raised $2.7 million to date, according to an SEC filing. This is Nucci’s first startup after selling his cloud computing company Boomi to Dell for an undisclose... |
| 11.12.2013 | Apprennet awarded $150K Science Foundation grant [Startup Roundup] | WHO’S GETTING FUNDED?
Apprennet, an online learning startup, was awarded a $150,000 National Science Foundation grant to study whether or not teacher participation on their platform affects teacher effectiveness, said cofounder Emily Foote.... |
| 20.11.2013 | Gene therapy startup launches with $5M and eyes toward a better treatment for hemophilia | Currently Dimension is working on IND-enabling studies of a drug candidate for hemophilia B, a hereditary bleeding disorder characterized by a lack of one of the proteins needed to form blood clots in the body. It can cause a person to expe... |
| - | Novartis, Spark make positive step toward gene therapy Luxturna’s European approval | The first gene therapy approved in the United States made a significant step toward winning approval in Europe as well as the European drug regulator’s expert committee adopted a positive opinion for its approval.
Swiss drugmaker Novartis a... |
| - | Gene editing remains early stage, but Big Pharma has taken notice | The field of gene editing is moving fast. In late October, two new papers described technologies that allow for the precise editing of individual DNA bases — an A to a T, a C to a G — and, separately, a mechanism for genetically editing RNA... |
| - | Pfizer and Sangamo ink a $545M hemophilia-gene therapy deal | Sangamo Therapeutics has lofty aims for its gene therapy programs — but at least one Big Pharma company thinks they’re achievable.
On Wednesday, the Richmond, California-based company announced a global collaboration and licensing agreement... |
| - | Navigating the challenge of covering breakthrough therapies at MedCity INVEST Precision Medicine | Our virtual MedCity INVEST Precision Medicine conference, December 9-11, will highlight aspects of precision medicine from the biopharma companies developing cell and gene therapies to diagnostics and the data sharing initiatives to support... |
| - | Gene therapy company Spark Therapeutics inks licensing deal for a retinitis pigmentosa gene therapy | Retinitis pigmentosa is the most common inherited eye disease. Mutations in the gene for rhodopsin, the pigment for photoreceptor cells in the retina responsible for the perception of light, account for 15 percent of retinitis pigmentosa ca... |
| - | Can Alnylam rise from the ASHes? | October was a bad month for Alnylam. Its shares plunged almost 50 percent after it abruptly scrapped its Phase 3 candidate revusiran, citing a disproportionate number of deaths in the active arm of the trial.
It was a major blow for the dou... |
| - | Sofinnova Ventures has raised $595M for its largest fund to date | Life sciences investor Sofinnova Ventures is raising fund number 10 in what, as FierceBiotech notes, appears to be its largest fund to date. A previous fund, dating back to 2014, raised $500 million.
The investment firm did not immediately ... |
| - | Genome editing and Personalized Medicine: What it is (and what it could be) | BURLINGTON, Mass. — When the first sequencing of a human genome was announced in 2003, a coalition of world leaders issued a statement declaring that researchers had “completely decoded all the chapters of the instruction book of human life... |
| - | Report: Takeda adopts value-based pricing for Crohn’s stem cell therapy in Europe | A Japanese drugmaker is using value-based pricing in Europe for an expensive cell therapy used to treat the autoimmune disorder Crohn’s disease.
Nikkei Asian Review reported Monday that Tokyo-based Takeda Pharmaceutical would adopt the mode... |
| - | Venture-backed healthcare deals rise to $2.7B in Q2 | About $13.88 billion in venture capital backed 974 deals in the second quarter, the highest level since the first quarter of 2001, according to a new report by CB Insights. Healthcare accounted for a significant part of that. About $2.7 bil... |
| - | Spark Therapeutics’ late-stage gene therapy for inherited blindness takes a $73M step forward | A Children’s Hospital of Philadelphia spinout with the potential to be the first to win U.S. FDA approval of a gene therapy is now funded through the rest of development of its lead treatment for inherited blindness.
Spark Therapeutics is i... |
| - | Installment payments could be used across gene therapy space, Spark CEO says | Payments over time are an attractive model for paying for expensive gene therapies, but things need to move faster on the policy end, the head of the first company to win Food and Drug Administration approval for a gene therapy said Wednesd... |
| - | Mark your calendars for our virtual INVEST Precision Medicine conference, December 9-11 | The vision of precision medicine is to enable doctors, researchers and others to more accurately predict and prescribe appropriate treatments based on individuals genetic profile and other factors. Our virtual MedCity INVEST Precision Medic... |
| - | A biotech CEO plans to charge up to $3 million for a gene therapy — but he'll offer a money-back guarantee if it doesn't work | Jean-Jacques Bienaimé, the CEO of BioMarin Pharmaceutical. BioMarin Pharmaceutical This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
The biotech BioMarin is preparing to launch its hemophil... |
| - | What’s Militia Hill Ventures’ take on biotech, cancer therapy investment? (Q&A) | Jane Holmes Hollingsworth is a Philadelphia-based serial healthcare entrepreneur with a couple of successful exits under her belt. Teva Pharmaceuticals snapped up migraine pain patch business NuPathe for $114 million and drug developer Auxi... |
| - | ‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price | BOSTON — The trouble had started over a decade ago, when the Hogans noticed something wasn’t right with their son Jack. As a baby, he would spend hours staring into the lights in his nursery. Later, he sometimes walked into walls or fell do... |
| - | Kids with 'bubble boy' disease are dying — even though drug companies have found a cure | This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Jakob Kamil Guziak lives in a bubble created by his parents.
Since he came home from the hospital in October 2019, three months ... |
| - | Spark Therapeutics adds regulatory insider to support gene therapy for retinal degeneration | A gene therapy spinout from Children’s Hospital of Philadelphia has added a head of regulatory affairs as it continues Phase 3 clinical trials for its treatment to reverse the effects of inherited retinal degeneration caused by a mutation i... |
| - | Gene therapy startup launches with $5M and eyes toward a better treatment for hemophilia | A newly formed gene therapy startup is taking gene delivery technology from ReGenX and a $5 million investment from Fidelity Biosciences to develop new treatments for rare diseases, starting with hemophilia.
ReGenX and Fidelity Biosciences ... |
| - | Spark Therapeutics’ new FDA approval shows gene therapies are officially on fire | It didn’t happen overnight, but gene therapy has officially arrived.
On Tuesday morning, the U.S. Food and Drug Administration announced its approval of Spark Therapeutics’ Luxturna (voretigene neparvovec-rzyl) a one-time treatment for adul... |
| - | Spark, Novartis’s inherited blindness therapy Luxturna wins approval in Europe | A gene therapy that was the first of its kind to receive Food and Drug Approval in the US has won approval from Europe’s main drug regulator as well.
Swiss drugmaker Novartis said Friday that the European Commission approved Luxturna (voret... |
| - | Sofinnova appears to be bulking up a healthcare venture fund to $110 million | Looks like Sofinnova Ventures is bulking up one of its venture funds – up from $50 million a year ago to $110 million today.
About $65 million of the Sofinnova HealthQuest Partners fund has been sold, with $45 million still remaining, accor... |
